Want to see IL:BLRX full AI Analyst Report?
Top Page
Bioline Rx
(TASE:BLRX)
Select Model
Select Model
Rating:45Neutral
Price Target:
1.50
▲(0.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance (sharp TTM revenue collapse, deep losses, and ongoing cash burn) and bearish technical positioning (price below key moving averages with negative MACD). The earnings call provides a partial offset due to solid clinical execution and stated funding runway into 1H 2027, but near-term fundamentals and loss-making status (negative P/E, no dividend) keep the overall profile cautious.
Positive Factors
GLIX1 clinical execution
GLIX1 recruitment is ahead of plan, multiple academic centers are enrolling, and safety and tolerability have remained encouraging. This execution supports development momentum and expands the evidence base for a potentially differentiated oncology asset, although value still depends on later clinical readouts.
Negative Factors
Severe revenue and profitability weakness
The sharp revenue collapse and deeply negative net margin show that current commercial income is far below the cost base. This weak earnings foundation limits internally funded investment, increases dependence on partnerships or financing, and makes financial performance highly sensitive to milestone timing.
Read all positive and negative factors
Positive Factors
Negative Factors
GLIX1 clinical execution
GLIX1 recruitment is ahead of plan, multiple academic centers are enrolling, and safety and tolerability have remained encouraging. This execution supports development momentum and expands the evidence base for a potentially differentiated oncology asset, although value still depends on later clinical readouts.
Read all positive factors
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪40.73M
Dividend YieldN/A
Average Volume (3M)2.73M
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth-93.07%
EPS Growth62.25%
CountryIL
Employees22
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,909,394,800
10 Day Avg. Volume4,445,089
30 Day Avg. Volume2,726,169
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)₪1.95M
Bioline Rx Business Overview & Revenue Model
Company Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the tre...
How the Company Makes Money
BiolineRx’s revenue model is primarily partnership-driven rather than based on broad internal commercial sales, reflecting its clinical-stage profile. The company makes money mainly through (1) collaboration and licensing arrangements for its drug...
Bioline Rx Earnings Call Summary
Earnings Call Date:Aug 31, 2026
(Q2-2026)
| Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call was predominantly positive, driven by strong GLIX1 clinical recruitment and tolerability, encouraging preclinical efficacy and combination data, progress in the pancreatic cancer trial, APHEXDA royalty generation, and funding expected to support operations into the first half of 2027. These positives were tempered by the higher quarterly net loss and R&D spending, flat revenue, the early stage of GLIX1 clinical development, uncertainty surrounding the pancreatic cancer treatment landscape, and the commercial work still required to expand APHEXDA adoption.Positive Updates
GLIX1 Clinical Trial Progressing Ahead of Plan
BioLineRx reported that recruitment to the Phase I/IIa GLIX1 trial in glioblastoma and other high-grade gliomas is going extremely well and that the trial continues to progress according to plan. Dosing began in the second of five planned Phase I cohorts last month, with the third cohort expected to begin dosing in September. The company has been pleased with GLIX1's safety and tolerability more than four months into the study and continues to anticipate Phase I data in the first half of 2027.
Negative Updates
Net Loss Increased Year Over Year
Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million, or approximately 10%.
Read all updates
Q2-2026 Updates
Positive
Negative
GLIX1 Clinical Trial Progressing Ahead of Plan
BioLineRx reported that recruitment to the Phase I/IIa GLIX1 trial in glioblastoma and other high-grade gliomas is going extremely well and that the trial continues to progress according to plan. Dosing began in the second of five planned Phase I cohorts last month, with the third cohort expected to begin dosing in September. The company has been pleased with GLIX1's safety and tolerability more than four months into the study and continues to anticipate Phase I data in the first half of 2027.
Read all positive updates
Company Guidance
BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned for when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.Bioline Rx Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
45
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.28M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 972.78K | 462.21K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -11.29M | -10.57M | 3.92M | -57.09M | -28.50M | -24.07M |
| Net Income | -7.96M | -1.27M | -9.22M | -60.61M | -20.75M | -28.14M |
Balance Sheet | ||||||
| Total Assets | 33.26M | 40.91M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 7.89M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 16.75M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 13.68M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -10.97M | -8.77M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -10.94M | -8.74M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 12.53M | -9.25M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -4.78M | 9.62M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline Rx Technical Analysis
Negative
1.50
Price Trends
1.49
Negative
1.48
Negative
1.52
Negative
Market Momentum
-0.03
Positive
42.51
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.5 is above the 20-day moving average (MA) of 1.46, above the 50-day MA of 1.49, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.51 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline Rx Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | ₪32.42M | >-0.01 | ― | 0.96% | ― | -125.74% | |
45 Neutral | ₪40.73M | -1.55 | ― | ― | -93.07% | 62.25% | |
41 Neutral | ₪21.84M | -0.54 | ― | ― | ― | ― | |
41 Neutral | ₪27.26M | -1.51 | ― | ― | -100.00% | -29.02% |
* General Sector Average
IL:BLRX
Bioline Rx
1.40
-0.70
-33.33%
IL:XTLB
Xtl Bio
1.80
-2.50
-58.14%
IL:CANF
Can Fite Bio
376.40
375.40
37540.00%
IL:BOLT
Biolight
300.20
-236.90
-44.11%
IL:PPBT
Purple Biotech
1.00
-0.20
-16.67%
IL:MTLF
Matricelf
299.70
-431.80
-59.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.